Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
EMERYVILLE, Calif., March 28, 2017 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, is scheduled to present at the Needham Healthcare Conference in New York on Tuesday, April 4, 2017 at 10:40 a.m. Eastern Time.
The presentation will be webcast live from the Investor section of the Adamas website at http://ir.adamaspharma.com/events.cfm and available through May 4, 2017.
About Adamas Pharmaceuticals, Inc.
Adamas develops new medicines to improve the daily lives of those affected by chronic neurologic disorders, including Parkinson’s disease, multiple sclerosis, epilepsy and Alzheimer’s disease. Adamas has pioneered a platform to develop medicines, called chrono-synchronous therapies, for chronic neurologic disorders based on an understanding of the time-dependent biologic processes responsible for disease activity and drug response to potentially achieve symptomatic relief without tolerability issues. The company’s most advanced product candidate, ADS-5102, is in development for levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease and walking impairment. An NDA supporting ADS-5102 for the treatment of LID in patients with Parkinson’s disease is under review by the FDA, with a PDUFA date of August 24, 2017. Adamas is exploring other indications for ADS-5102 for further development. Adamas is also investigating ADS-4101 for the treatment of partial onset seizures in patients with epilepsy. Additionally, Adamas’ licensed assets, NAMENDA XR® and NAMZARIC®, are currently marketed by Allergan, and Adamas is eligible to receive royalties on sales of these medicines beginning in June 2018 and May 2020, respectively. For more information, please visit www.adamaspharma.com.
NAMENDA XR® and NAMZARIC® are trademarks of Merz Pharma GmbH & Co. KGaA.
Contact: Ashleigh Barreto Director, Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. 510-450-3567 [email protected]
